Search company, investor...
Eleva company logo

Eleva

elevabiologics.com

Stage

Unattributed | Alive

Total Raised

$73.66M

Last Raised

$73.66M | 2 yrs ago

About Eleva

Eleva utilizes a moss-based platform to produce novel drugs.

Headquarters Location

Hans-Bunte-Str. 19

Freiburg, 79108,

Germany

+49 761 470 99 0

Missing: Eleva's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Eleva's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Eleva

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Eleva is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Eleva Patents

Eleva has filed 1 patent.

The 3 most popular patent topics include:

  • Autosomal recessive disorders
  • Biotechnology
  • Molecular biology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/17/2016

8/2/2022

Autosomal recessive disorders, Rare diseases, Clusters of differentiation, Molecular biology, EC 3.2.1

Grant

Application Date

3/17/2016

Grant Date

8/2/2022

Title

Related Topics

Autosomal recessive disorders, Rare diseases, Clusters of differentiation, Molecular biology, EC 3.2.1

Status

Grant

Latest Eleva News

Eleva Enters Clinical Development Of Difficult-To-Express High-Potential Proteins

Oct 12, 2021

Eleva Enters Clinical Development Of Difficult-To-Express High-Potential Proteins FREIBURG, Germany, Oct. 12, 2021 /PRNewswire/ -- Eleva, a manufacturer of superior biologics, is entering clinical phases with its own drug candidates, such as immune-regulating factor H, as well as in collaboration with pharmaceutical partners. Author: FREIBURG, Germany, Oct. 12, 2021 /PRNewswire/ -- Eleva, a manufacturer of superior biologics, is entering clinical phases with its own drug candidates, such as immune-regulating factor H, as well as in collaboration with pharmaceutical partners. Its moss-based platform is ideally suited to produce difficult-to-express but therapeutically promising drug candidates. Its recently expanded production capacity enables Eleva to conduct clinical studies of its drug candidates. Among the first ones is factor H which will be developed through phase II. Up to 2,500 l will be produced in state-of-the-art single-use reactors at a GMP site. Eleva's moss-based platform offers unique advantages for recombinant protein development, such as: Moss glycostructure naturally lacks core α-1,6 fucose - a known allergen - while any other glycans can be "humanized". This leads to excellent organ uptake. Being a plant, it will not be contaminated with animal pathogens, which eliminates the need for antibiotics. The moss production system, haploid by nature, is based on an intact organism, not on cell cultures. This guarantees exceptionally stable modifications. Eleva is leveraging those advantages to produce complex proteins for future therapies, such as 2 nd generation oncological therapeutics, or virus-like-particles (VLP) for vaccine development. Ralf Smit, CBO of Eleva: "With production scaling up, we can now offer to develop difficult-to-express therapeutic proteins in collaboration with partners in the pharmaceutical industry. We look forward to our moss platform unlocking the very promising potential of complex candidates for the benefit of patients." About Eleva Based in Freiburg, Germany, Eleva develops novel biological therapies with its pharmaceutical partners. The privately-held company leverages its unique moss-based production platform to produce supreme biologics like antibodies, replacement enzymes, or fusion toxins. Eleva has successfully developed drug candidates into clinical phases. Press contact SOURCE eleva GmbH

Eleva Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Eleva Rank

Eleva Frequently Asked Questions (FAQ)

  • Where is Eleva's headquarters?

    Eleva's headquarters is located at Hans-Bunte-Str. 19, Freiburg.

  • What is Eleva's latest funding round?

    Eleva's latest funding round is Unattributed.

  • How much did Eleva raise?

    Eleva raised a total of $73.66M.

  • Who are the investors of Eleva?

    Investors of Eleva include Zukunftsfonds Heilbronn.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.